新型抗肥胖疗法及其不同的效果和安全性概况：批判性综述
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.
作者信息
Telci Caklili Ozge, Cesur Mustafa, Mikhailidis Dimitri P, Rizzo Manfredi
机构信息
Department of Endocrinology and Metabolism, Faculty of Medicine, University of Istanbul, Istanbul, Türkiye.
Department of Endocrinology and Metabolism, Ankara Guven University Hospital, Ankara, Türkiye.
出版信息
Diabetes Metab Syndr Obes. 2023 Jun 14;16:1767-1774. doi: 10.2147/DMSO.S392684. eCollection 2023.
Abstract
Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.
摘要
肥胖已成为一种流行病和全球性问题，其治疗方法也在不断发展。除饮食和运动外，药物治疗和手术也是其他选择。在各种减肥药出现令人失望的副作用后，新的治疗方法显示出了有希望的结果。本综述讨论了以下抗肥胖药物：利拉鲁肽、司美格鲁肽、替尔泊肽、奥利司他，以及苯丁胺/托吡酯和安非他酮/纳曲酮组合。除仍在评估中的替尔泊肽外，这些药物均已获得美国食品药品监督管理局（FDA）批准用于减肥。其中一些药物的疗效和可耐受的安全性有助于肥胖的管理，并减少与这种慢性病相关的并发症。
相似文献
1
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.
Diabetes Metab Syndr Obes. 2023 Jun 14;16:1767-1774. doi: 10.2147/DMSO.S392684. eCollection 2023.
2
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Endocr Metab Immune Disord Drug Targets. 2020;20(8):1232-1243. doi: 10.2174/1871530320666200515112853.
3
Drugs for Treating Obesity.
Handb Exp Pharmacol. 2022;274:387-414. doi: 10.1007/164_2021_560.
4
Drug treatment of obesity: current status and future prospects.
Eur J Intern Med. 2015 Mar;26(2):89-94. doi: 10.1016/j.ejim.2015.01.005. Epub 2015 Jan 26.
5
Long-term effects of weight-reducing drugs in people with hypertension.
Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4.
6
Current and emerging pharmacotherapies for obesity in Australia.
Obes Res Clin Pract. 2017 Sep-Oct;11(5):501-521. doi: 10.1016/j.orcp.2017.07.002. Epub 2017 Aug 14.
7
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
Obesity (Silver Spring). 2023 May;31(5):1270-1279. doi: 10.1002/oby.23725. Epub 2023 Feb 23.
8
FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade.
Cureus. 2022 Sep 17;14(9):e29262. doi: 10.7759/cureus.29262. eCollection 2022 Sep.
9
A narrative review of approved and emerging anti-obesity medications.
Saudi Pharm J. 2023 Oct;31(10):101757. doi: 10.1016/j.jsps.2023.101757. Epub 2023 Aug 24.
10
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.
Gastroenterology. 2022 Nov;163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20.
引用本文的文献
1
Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.
Diabetes Metab Syndr Obes. 2025 Aug 7;18:2723-2738. doi: 10.2147/DMSO.S531697. eCollection 2025.
2
PEG-Coated Ceria-Zirconia Nanoparticle Prevent Weight Gain and Obesity-Related Organ Damage Through Autophagy Flux Activation and ROS Scavenging.
Int J Nanomedicine. 2025 Jun 26;20:8305-8326. doi: 10.2147/IJN.S510541. eCollection 2025.
3
Mechanisms underlying obesity-malignancy connection: a systematic narrative review.
J Physiol Biochem. 2025 May 23. doi: 10.1007/s13105-025-01084-9.
4
Clinical studies on anti-obesity medications in Arab countries.
Saudi Med J. 2025 May;46(5):459-477. doi: 10.15537/smj.2025.46.5.20250126.
5
Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.
Int J Obes (Lond). 2025 Mar;49(3):492-506. doi: 10.1038/s41366-025-01729-1. Epub 2025 Feb 27.
6
Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.
Neuropharmacology. 2025 Mar 1;265:110269. doi: 10.1016/j.neuropharm.2024.110269. Epub 2024 Dec 14.
7
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.
Diabetes Ther. 2024 Sep;15(9):1865-1892. doi: 10.1007/s13300-024-01615-5. Epub 2024 Jul 11.
8
The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets.
Diabetes Metab Syndr Obes. 2024 Jun 13;17:2419-2456. doi: 10.2147/DMSO.S415934. eCollection 2024.
本文引用的文献
1
Semaglutide in Obesity: Unmet Needs in Men.
Diabetes Ther. 2023 Mar;14(3):461-465. doi: 10.1007/s13300-022-01360-7. Epub 2023 Jan 7.
2
Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
Obes Rev. 2023 Mar;24(3):e13543. doi: 10.1111/obr.13543. Epub 2022 Dec 29.
3
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221146371. doi: 10.1177/10742484221146371.
4
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.
Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009.
5
Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.
Obesity (Silver Spring). 2023 Jan;31(1):74-82. doi: 10.1002/oby.23596. Epub 2022 Dec 7.
6
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.
7
The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact.
Diabetes Ther. 2022 Oct;13(10):1723-1736. doi: 10.1007/s13300-022-01311-2. Epub 2022 Aug 27.
8
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
Lancet Diabetes Endocrinol. 2022 Sep;10(9):623-633. doi: 10.1016/S2213-8587(22)00188-7. Epub 2022 Jul 30.
9
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
10
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study.
Diabetes Ther. 2022 Mar;13(3):453-464. doi: 10.1007/s13300-022-01217-z. Epub 2022 Feb 15.
Zotero 插件